$0.38
0.00%
Nasdaq, Mon, Nov 25 2024
ISIN
US64132K1025
Symbol
NBSE
Sector
Industry

NeuBase Therapeutics Inc Stock price

$0.38
+0.00 0.00% 1M
+0.00 0.00% 6M
-0.36 48.93% YTD
-0.27 42.02% 1Y
-64.82 99.42% 3Y
-129.42 99.71% 5Y
-2,955.62 99.99% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
US64132K1025
Symbol
NBSE
Sector
Industry

Key metrics

Market capitalization $1.41m
Enterprise Value $-5.82m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.37
P/B ratio (TTM) P/B ratio 0.15
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-17.16m
Free Cash Flow (TTM) Free Cash Flow $-15.77m
Cash position $12.57m
EPS (TTM) EPS $-9.76
Short interest 0.44%
Show more

Is NeuBase Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

NeuBase Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a NeuBase Therapeutics Inc forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a NeuBase Therapeutics Inc forecast:

Buy
33%
Hold
67%

Financial data from NeuBase Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
- -
-
100%
- Direct Costs 1.19 1.19
6% 6%
-
-1.19 -1.19
6% 6%
-
- Selling and Administrative Expenses 7.09 7.09
30% 30%
-
- Research and Development Expense 7.69 7.69
63% 63%
-
-16 -16
50% 50%
-
- Depreciation and Amortization 1.19 1.19
6% 6%
-
EBIT (Operating Income) EBIT -17 -17
48% 48%
-
Net Profit -17 -17
50% 50%
-

In millions USD.

Don't miss a Thing! We will send you all news about NeuBase Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington's Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.

Head office United States
CEO Todd Branning
Founded 2009
Website www.neubasetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today